98%
921
2 minutes
20
The pretargeted imaging strategy using inverse electron demand Diels-Alder (IEDDA) cycloaddition between a -cyclooctene (TCO) and tetrazine (Tz) has emerged and rapidly grown as a promising concept to improve radionuclide imaging and therapy in oncology. This strategy has mostly relied on the use of radiolabeled Tz together with TCO-modified targeting vectors leading to a rapid growth of the number of available radiolabeled tetrazines, while only a few radiolabeled TCOs are currently reported. Here, we aim to develop novel and structurally diverse F-labeled cis-dioxolane-fused TCO (d-TCO) derivatives to further expand the bioorthogonal toolbox for ligation and evaluate their potential for positron emission tomography (PET) pretargeted imaging. A small series of d-TCO derivatives were synthesized and tested for their reactivity against tetrazines, with all compounds showing fast reaction kinetics with tetrazines. A fluorescence-based pretargeted blocking study was developed to investigate the ligation of these compounds without labor-intensive prior radiochemical development. Two compounds showed excellent ligation results with blocking efficiencies of 95 and 97%. Two novel F-labeled d-TCO radiotracers were developed, from which [] showed good stability, favorable pharmacokinetics, and moderate stability. Micro-PET pretargeted imaging with [] in mice bearing LS174T tumors treated with tetrazine-modified CC49 monoclonal antibody (mAb) (CC49-Tz) showed significantly higher uptake in tumor tissue in the pretargeted group (CC49-Tz 2.16 ± 0.08% ID/mL) when compared to the control group with nonmodified mAb (CC49 1.34 ± 0.07% ID/mL). A diverse series of fast-reacting fluorinated d-TCOs were synthesized. A pretargeted blocking approach in tumor-bearing mice allowed the choice of a lead compound with fast reaction kinetics with Tz. A novel F-labeled d-TCO tracer was developed and used in a pretargeted PET imaging approach, allowing specific tumor visualization in a mouse model of colorectal cancer. Although further optimization of the radiotracer is needed to enhance the tumor-to-background ratios for pretargeted imaging, we anticipate that the F-labeled d-TCO will find use in studies where increased hydrophilicity and fast bioconjugation are required.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586181 | PMC |
http://dx.doi.org/10.1021/acsomega.3c04597 | DOI Listing |
Mol Pharm
August 2025
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, P. R. China.
Biologically active molecules, such as carbohydrates, peptides, and proteins, are attractive candidates for positron emission tomography (PET) imaging because of their strong target affinity and biocompatibility. Among available radionuclides, fluorine-18 (F) is widely used in clinical practice because of its moderate half-life and high-quality imaging properties. However, traditional F-labeling methods often require a laborious procedure and harsh conditions, which may compromise the structural integrity and biological functions.
View Article and Find Full Text PDFNucl Med Commun
August 2025
Department of Nuclear Medicine, the Second Affiliated Hospital of Soochow University, Suzhou City, China.
As a promising approach, in vivo pretargeting can leverage the unique tumor-targeting properties of antibodies for nuclear imaging and therapy while bypassing their pharmacokinetic limitations. The core premise of pretargeting is that targeted vectors and radioisotopes are administered separately, leading to a higher target background ratio than traditional imaging methods using long-lived radionuclides. This strategy directly relies on chemical reactions, namely bioorthogonal reactions.
View Article and Find Full Text PDFBioconjug Chem
August 2025
Genentech Research and Early Development, Department of Translational Pharmacokinetics and Pharmacodynamics, South San Francisco, California 94080, United States.
Achieving a rapid image contrast is a critical attribute of successful imaging biomarkers of T-cell redirecting cancer immunotherapies, as even small shifts in the cluster of differentiation 8 (CD8) expressing T cell populations can be associated with meaningful therapeutic responses. However, T cell imaging agents, such as one-armed (OA) anti-CD8 monoclonal antibodies, are often limited by high renal uptake and poor resolution against the systemic blood signal. Herein we evaluate antibody pretargeting with and without the abrogation of binding to the neonatal Fc receptor (FcRn) as strategies to enhance the tumor contrast of OA antibodies targeting the minimally internalizing receptor, CD8.
View Article and Find Full Text PDFAppl Radiat Isot
November 2025
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Den
Fluorescence intraoperative guided surgery (FIGS) allows surgeons to resect tumors more completely - without damaging or removing healthy tissue. We have recently shown that pretargeted FIGS can improve contrast between malignances and healthy tissue. Therefore, pretargeted FIGS has the potential to improve conventional FIGS.
View Article and Find Full Text PDFTheranostics
August 2025
Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
Curative therapies remain a significant unmet need for advanced human colorectal cancer (CRC). The aim of this study was to establish a 3-step Ac-DOTA pretargeted radioimmunotherapy (PRIT) system for human CRC, targeting two individual antigens: glycoprotein A33 (GPA33) and human epidermal growth factor receptor 2 (HER2). cellular uptake and internalization assays, as well as survival assays (colony forming) were performed in GPA33- and HER2-positive SW1222 human CRC cells.
View Article and Find Full Text PDF